Editorial & Opinion
أعرض في EDS

Attack of the clones: Unveiling subclonal/heterogenous mismatch repair/microsatellite instability status in endometrial cancer.

التفاصيل البيبلوغرافية
العنوان: Attack of the clones: Unveiling subclonal/heterogenous mismatch repair/microsatellite instability status in endometrial cancer.
المؤلفون: Grither WR; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA., Hagemann IS; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA., Powell MA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA., Mullen MM; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA.
المصدر: Cancer [Cancer] 2024 Feb 01; Vol. 130 (3), pp. 339-341. Date of Electronic Publication: 2023 Oct 30.
نوع المنشور: Editorial; Comment
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005- >: Hoboken, NJ : Wiley
Original Publication: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.]
مواضيع طبية MeSH: DNA Mismatch Repair*/genetics , Endometrial Neoplasms*/genetics, Female ; Humans ; Microsatellite Instability ; Biomarkers, Tumor ; Clone Cells/metabolism ; MutL Protein Homolog 1/genetics
التعليقات: Comment on: Cancer. 2024 Feb 1;130(3):385-399. (PMID: 37751191)
References: McMeekin DS, Tritchler DL, Cohn DE, et al. Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2016;34(25):3062-3068. doi:10.1200/jco.2016.67.8722.
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73. doi:10.1038/nature12113.
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413. doi:10.1126/science.aan6733.
Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388(23):2145-2158. doi:10.1056/nejmoa2216334.
O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40(7):752-761. doi:10.1200/jco.21.01874.
Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159-2170. doi:10.1056/nejmoa2302312.
Makker V, Colombo N, Casado Herraez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437-448. doi:10.1056/nejmoa2108330.
Engel KB, Moore HM. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2011;135(5):537-543. doi:10.5858/2010-0702-rair.1.
Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232-1243. doi:10.1093/annonc/mdz116.
Raffone A, Travaglino A, Cerbone M, et al. Diagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer. Pathol Oncol Res. 2020;26(3):1417-1427. doi:10.1007/s12253-020-00811-5.
Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn. 2008;10(4):301-307. doi:10.2353/jmoldx.2008.080062.
Stelloo E, Jansen AML, Osse EM, et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol. 2017;28(1):96-102. doi:10.1093/annonc/mdw542.
Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene. 1998;17(18):2413-2417. doi:10.1038/sj.onc.1202178.
Riedinger CJ, Esnakula A, Haight PJ, et al. Characterization of mismatch repair (MMR)/microsatellite instability (MSI)-discordant endometrial cancers. Cancer. 2023;000:000-000. doi:10.1002/cncr.35030.
Pai RK, Plesec TP, Abdul-Karim FW, et al. Abrupt loss of MLH1 and PMS2 expression in endometrial carcinoma: molecular and morphologic analysis of 6 cases. Am J Surg Pathol. 2015;39(7):993-999. doi:10.1097/pas.0000000000000415.
Watkins JC, Nucci MR, Ritterhouse LL, Howitt BE, Sholl LM. Unusual mismatch repair immunohistochemical patterns in endometrial carcinoma. Am J Surg Pathol. 2016;40(7):909-916. doi:10.1097/pas.0000000000000663.
Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10(4):293-300. doi:10.2353/jmoldx.2008.080031.
Rakha EA, Chmielik E, Schmitt FC, Tan PH, Quinn CM, Gallagy G. Assessment of predictive biomarkers in breast cancer: challenges and updates. Pathobiology. 2022;89(5):263-277. doi:10.1159/000525092.
Cote ML, Ruterbusch JJ, Olson SH, Lu K, Ali-Fehmi R. The growing burden of endometrial cancer: a major racial disparity affecting Black women. Cancer Epidemiol Biomarkers Prev. 2015;24(9):1407-1415. doi:10.1158/1055-9965.epi-15-0316.
Vikas P, Messersmith H, Compton C, et al. Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline. J Clin Oncol. 2023;41(10):1943-1948. doi:10.1200/jco.22.02462.
فهرسة مساهمة: Keywords: discordant results; endometrial cancer; mismatch repair (MMR); prognostication
المشرفين على المادة: 0 (Biomarkers, Tumor)
EC 3.6.1.3 (MutL Protein Homolog 1)
تواريخ الأحداث: Date Created: 20231030 Date Completed: 20240202 Latest Revision: 20240311
رمز التحديث: 20240312
DOI: 10.1002/cncr.35067
PMID: 37902951
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-0142
DOI:10.1002/cncr.35067